Skip to main content

Talk Bio

Search This Blog

Hansoh Hits Phase III SCLC Goal

on July 13, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Hansoh Pharmaceutical Group has announced positive Phase III results in small-cell lung cancer (SCLC) with its B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez, HS-20093), and the U.S. FDA has approved Sanofi’s on-body injector (OBI) for the subcutaneous version of its multiple myeloma drug Sarclisa (Sarclisa Escena).

Sources:

GSK's licensor Hansoh Pharma announces positive phase ...

Press Release: Sanofi's subcutaneous Sarclisa Escena ...

Sanofi's Sarclisa Escena FDA Approved On-Body Injector - AllSci

ARTEMIS-008：HS-20093 Compared With Topotecan in... | 临床试验

Press Releases-Hansoh Pharmaceutical Group Co., Ltd.

Hansoh Pharmaceutical (3692.HK) - 富途资讯

Hansoh Pharma's Aumolertinib Plus Chemotherapy Shows Positive ...

Hansoh Pharmaceutical: Oncology Pipeline Catalysts and Strategic ...

This designation is for treating extensive-stage small cell lung ...

NCT07464327 | A Phase III Study of HS-20093 Injection Combined ...

Hansoh B7-H3 ADC Wins Phase III SCLC Trial

Jiangsu Hansoh Pharma News

ARTEMIS-008 CD276 gene Escena Hansoh Pharma HS-20093 on-body injector Overall Survival Phase III SCLC trial risvutatug rezetecan sanofi Sarclisa therapeutic autologous dendritic cells topotecan

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Powered by Blogger

X-Data LLC